Application of Platelet-Rich Fibrin on Diabetic Foot Wound

January 31, 2023 updated by: Ebru ÇELEBİ, Abant Izzet Baysal University

Investigation of the Effect of Platelet Rich Fibrin (PRF) Application on Wound Healing in Diabetic Foot Wound

This study was planned as a prospective case-control study to examine the effect of PRF application on wound healing in diabetic foot wound. The sample of the study will consist of patients with diabetic foot wounds, who met the inclusion criteria and agreed to participate in the study. It is planned to include 7 patients for the experimental group and 7 patients for the control group (14 patients in total). If the patient is in the experimental group, PRF will be applied to the diabetic foot wound, and in the control group, classic wound dressing (CWD) will be applied.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Foot ulcer is a common complication in diabetic patients, in some cases requiring hospitalization and may result in amputation. Effective treatment and care of diabetic foot is as important as prevention. For this reason, the condition of the wound should be evaluated well, effective wound care materials should be used, and current evidence-based practices should be included in treatment and care. One of these current applications is PRF. In the literature, the success and positive effects of PRF applications on dentistry, plastic surgery, orthopedics, eye surgery, diabetic foot, chronic arterial and venous ulcers, and complex wounds that are difficult to heal have been reported.

This study was planned as a prospective case-control study to examine the effect of PRF application on wound healing in diabetic foot wound. The population of the study will consist of patients with diabetic foot wounds, who applied to Bolu Home Health Services affiliated to the Republic of Turkey Ministry of Health Bolu Provincial Health Directorate, and who were followed up in the center of Bolu.

The sample of the study will consist of patients with diabetic foot wounds, who met the inclusion criteria and agreed to participate in the study. It is planned to include 7 patients for the experimental group and 7 patients for the control group (14 patients in total). Before starting the study, patients will be randomized in a computer program (random.org). According to the randomization results of the program, the patients in the first column will be the experimental group and the patients in the second column will be the control group. If the patient is in the experimental group, PRF will be applied to the diabetic foot wound, and in the control group, classic wound dressing (CWD) will be applied.

PRF Preparation and Application Technique (To be applied to the experimental group):

10 ml blood will be collected into a tube without anticoagulant with an injector or a vacutainer directly, from the patients included in the experimental group. Then, centrifugation will be carried out immediately at 3000 (rpm) speed for 10 minutes. This process will be applied by the researcher next to the patient by using a Yuda 800D brand desktop type centrifuge device with 6 tube capacity, 500-4000 rpm speed setting and 5-30 minutes time setting. After this procedure, the tube will be removed from the device and the PRF clot formed in the middle of the tube will be removed with forceps. This clot will be compressed into a membrane between two sterile gauzes moistened with saline, with as little finger pressure as possible. The shaped PRF will be placed to cover the entire diabetic foot wound under sterile conditions. Then the dressing will be closed by covering with sterile gauze.These applications will be repeated weekly and applied for a total of 11 weeks.

Classic Wound Dressing Application:

Classic dressing will be applied to the diabetic foot wound of the patients in the control group by the researcher. After the diabetic foot wound is evaluated, it will be irrigate with saline on sterile conditions, cover with sterile gauze and fix with a plaster. This dressing will be repeated weekly and applied for a total of 11 weeks.

Wound evaluation will be done at 1st (first day of application), 2nd, 4th, 8th and 12th weeks. "Data collection form", "Wound observation and evaluation form", 'Diabetes Self-Efficacy Scale', 'Diabetic Foot Care Self-Efficacy Scale', 'Medical Adherence Report Scale' will be used in the data collection phase of the research. The evaluation of both feet in terms of diabetic foot will be made using the 'Diabetic Foot Evaluation Form'. In addition, diabetic foot care training will be given to all patients at the first meeting.

In the power analysis (G*Power 3.1.9.4) made considering the studies in the literature, it was determined that at least 12 patients (6 experiment, 6 control) should be reached for the study. Problems that may arise with the participants during the study were taken into account, and it is planned to include at least 7 patients (14 in total) for each group, by overestimating 1 person for each of the two groups. The data will be evaluated using a statistical package program. Evaluation will be made by using various tests (dependent/independent t-test, Mann Whitney U, Wilcoxon, Kruskal Wallis, Dependent/Independent ANOVA, Friedman, etc.) and correlation tests, depending on whether the data show a normal distribution with descriptive statistical methods. The significance level to be used was determined as 0.05.

Study Type

Interventional

Enrollment (Anticipated)

14

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 1st or 2nd degree diabetic foot wound according to Wagner classification
  • Absence of infection in diabetic foot wound
  • Being over 18 years old
  • Willingness to participate in the research
  • Absence of any allergic disease
  • Absence of bleeding disorder
  • Not receiving corticosteroid treatment
  • Not using anticoagulant medication
  • Not smoking
  • Absence of circulatory disorders in the lower extremities
  • HbA1c value below 12% (Mean blood glucose value 298 mg/dL) in the most recent examination

Exclusion Criteria:

  • 3rd, 4th and 5th degree diabetic foot wound according to Wagner classification
  • Presence of infection in diabetic foot wound
  • Being under the age of 18
  • Not being willing to participate in the research
  • Presence of any allergic disease
  • Having a bleeding disorder
  • Being on corticosteroid treatment
  • Using anticoagulant medication
  • Smoking
  • HbA1c value above 12% (average blood glucose value 298 mg/dL) in the most recent examination
  • Having circulatory disorders in the lower extremities

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: SUPPORTIVE_CARE
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: PRF
If the patient is in the experimental group, platelet rich fibrin will be applied to the diabetic foot wound.
Platelet-rich fibrin preparation and application technique will applied to the experimental group.
NO_INTERVENTION: CWD
If the patient is in the control group, classic wound dressing will be applied to the diabetic foot wound.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Wound Observation and Evaluation Form
Time Frame: Healing on diabetic foot wounds at 12 weeks.
The length, width, depth, exudate, necrotic tissue, wound bed, skin around the wound, etc. aspects will be evaluated with this form.
Healing on diabetic foot wounds at 12 weeks.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Arzu İLÇE, Ph.D, Abant Izzet Baysal University
  • Study Director: Muhammed Emin DEMİRKOL, M.D., Abant Izzet Baysal University
  • Principal Investigator: Ebru ÇELEBİ, MSc, Abant Izzet Baysal University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

February 15, 2023

Primary Completion (ANTICIPATED)

October 30, 2023

Study Completion (ANTICIPATED)

August 30, 2024

Study Registration Dates

First Submitted

July 28, 2022

First Submitted That Met QC Criteria

July 29, 2022

First Posted (ACTUAL)

August 2, 2022

Study Record Updates

Last Update Posted (ACTUAL)

February 1, 2023

Last Update Submitted That Met QC Criteria

January 31, 2023

Last Verified

January 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetic Foot

Clinical Trials on PRF

3
Subscribe